Pharmaceuticals News and Research

RSS

Amira identifies novel pre-clinical candidate for autotaxin lysophosphatidic acid related program

Amira Pharmaceuticals, Inc. announced today that it has successfully identified a novel pre-clinical candidate for its newest lysophosphatidic acid (LPA)-related program, autotaxin. Autotaxin is an enzyme upstream from LPA receptors and has been implicated in a number of diseases including rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid cancers.

17 Dec 2010

Possible stem cell cure for AIDS

An explosion of stem cell breakthroughs, including a possible cure for AIDS, is reshaping the possibilities for curing deadly and debilitating diseases around the globe, says Emerging Healthcare Solutions President and CEO Cindy Morrissey.

17 Dec 2010

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

DiaGenic ASA and Pfizer Inc today signed an agreement for explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies.

17 Dec 2010

Celator granted U.S. Patent covering CombiPlex technology platform

Celator Pharmaceuticals today announced the United States Patent and Trademark Office issued U.S Patent No. 7,850,990. This patent adds to the intellectual property surrounding Celator's innovative technology platforms and products.

17 Dec 2010

NASDAQ OMX Stockholm promotes Medivir to Mid Cap List

Medivir AB, the emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that NASDAQ OMX Stockholm is promoting Medivir AB (MVIR B) from the Small Cap to the Mid Cap List. The change is effective as of January 3, 2011.

17 Dec 2010

Children's Hospitals and Clinics of Minnesota praises fix of orphan drug discount under 340B program

Families who were facing the prospect of huge increases in the cost of life-saving drugs for their children can breath easier thanks to a new law that will preserve discounts on specialized, so-called "orphan drugs."

17 Dec 2010

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).

17 Dec 2010

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, presented new data at the 2010 International Chemical Congress of Pacific Basin Societies, being held in Honolulu, Hawaii, December 15-20.

17 Dec 2010

GSK, Impax enter global development, commercialization agreement for PD investigational product, IPX066

GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (Impax), today announced an agreement for the development and commercialization of IPX066, Impax's novel extended release carbidopa-levodopa product, outside the United States and Taiwan. IPX066, an investigational product under development for the treatment of Parkinson's Disease (PD), is currently in Phase III clinical trials.

17 Dec 2010

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Recordati and Nymox Pharmaceutical Corporation announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).

17 Dec 2010

Ventrus prices initial public offering at $6.00 per share

Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at $6.00 per share. The shares are expected to begin trading tomorrow, December 17, 2010 on the Nasdaq Capital Market under the symbol "VTUS". In addition, Ventrus has granted the underwriters a 45-day option to purchase up to an additional 435,000 shares to cover over-allotments, if any.

17 Dec 2010

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Anacor Pharmaceuticals announced today that enrollment has been initiated and the first patient has been dosed in the Phase 3 program of AN2690, a topical antifungal product candidate for the treatment of onychomycosis.

16 Dec 2010

Gene variant linked to liver cirrhosis in Caucasians

A new study by German researchers found that a variation in the PNPLA3 (adiponutrin) gene was associated with cirrhosis of the liver and elevated transaminase (liver enzyme) levels in alcoholic Caucasians. The risk of cirrhosis in alcoholics in the genetic high risk group might be as high as 25 to 50%. Full findings are published in the January 2011 issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

16 Dec 2010

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Manhattan Pharmaceuticals, Inc. announced preliminary results today from a Phase 1/2 study of AST-915 for the treatment of essential tremor. Data from this single dose study demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power.

16 Dec 2010

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.

16 Dec 2010

Gene variation linked to liver cirrhosis in alcoholic caucasians

16 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Orexo AB and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007.

16 Dec 2010

Precise method to measure telomeres

Life Length, S.L. is a new biotechnology company set up to measure the length of telomeres which form caps at the end of chromosomes and that have a fundamental role in avoiding the break down and the aging of cells and organisms. The breakthroughs that Dr. Maria Blasco has made at the Spanish National Cancer Research Centre (Centro Nacional de Investigaciones Oncologicas, or CNIO) in Madrid, Spain form the founding basis of the company.

16 Dec 2010

Pharmaceuticals News and Research

Amira identifies novel pre-clinical candidate for autotaxin lysophosphatidic acid related program

Possible stem cell cure for AIDS

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

Celator granted U.S. Patent covering CombiPlex technology platform

NASDAQ OMX Stockholm promotes Medivir to Mid Cap List

Children's Hospitals and Clinics of Minnesota praises fix of orphan drug discount under 340B program

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

GSK, Impax enter global development, commercialization agreement for PD investigational product, IPX066

Bayer's SAFYRAL oral contraceptive receives FDA approval

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Ventrus prices initial public offering at $6.00 per share

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Gene variant linked to liver cirrhosis in Caucasians

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Gene variation linked to liver cirrhosis in alcoholic caucasians

Adeona expands and enhances zinc-based product candidate portfolio

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Precise method to measure telomeres

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence